$PRVB As a very respected analyst who knows this company extremely well recently told me, expect to see major pharma take interest in some of the smaller names that have fallen to deeply discounted levels. If he is correct in his thesis, and its certainty makes sense, Provention should be on the top of a few short lists.
  • 10
  • 13